Biogen | BIIB - Les Charges D'Exploitation

Prix De L'Action
186.72
Variation Quotidienne
-2.56 -1.35%
Mensuellement
5.29%
Annuel
51.15%
Q2 Prévisions
180.43




Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Amgen USD 4.78B 1.12B 2026-03
Bayer EUR 10.33B 126M 2025-12
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12